secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANI PHARMACEUTICALS INC (ANIP)
CIK:        0001023024
Form:       8-K
Filed at:   2026-08-24T11:01:19+00:00
Accession:  0001023024-26-000071
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ANI Pharmaceuticals appoints Henry Gosebruch to board; director Shanmugam resigns
--------------------------------------------------------------------------------

- Henry Gosebruch appointed to ANI board effective Aug 19, 2026; term expires at 2027 annual meeting.
- Gosebruch is CEO of Lakefront Biotherapeutics (formerly Galapagos) since May 2025; ex-CEO of Neumora, ex-EVP Chief Strategy Officer at AbbVie.
- Gosebruch receives initial restricted stock award with grant date fair value $525,000, vesting in 3 equal annual installments.
- Samy Shanmugam resigned as director effective Aug 23, 2026; remains Head of R&D and COO of New Jersey Operations.
- Gosebruch brings 30+ years experience; expected to strengthen business development and capital allocation as ANI accelerates Rare Disease transformation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1023024/000102302426000071/0001023024-26-000071-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1023024/000102302426000071/ani-20260819.htm
  HTML page:      https://secwatch.observer/filing/0001023024-26-000071

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer